Recruiting

Intermittent Catheter

Sponsor:

Hollister Incorporated

Code:

NCT07714694

Conditions

Urinary Retention

Neurogenic Bladder

Eligibility Criteria

Sex: Male

Age: 22+

Healthy Volunteers: Not accepted

Interventions

An intermittent urethral urinary catheter with a tip, tube and drainage eyelets

Study Details

Brief summary:

This clinical study is designed to evaluate the initial safety and performance of an investigational intermittent urinary catheter in people who use intermittent catheterization. Participants will use the study catheter and provide feedback on their experience, including ease of insertion, advancement through the urethra, bladder drainage, withdrawal, comfort, confidence, satisfaction, and overall ease of use.

Safety will be evaluated through reported health changes and adverse events. Device performance and user experience will be assessed using participant questionnaires and comparisons with the participant's current intermittent catheter, including questions related to catheter handling, comfort during catheterization, perceived ability to empty the bladder, likelihood of future use, and product preference.

The study is intended to generate descriptive information on the initial clinical use of the investigational catheter and to help characterize its safety, usability, comfort, satisfaction, and performance relative to participants' current intermittent catheter products.

Conditions

Urinary Retention

Neurogenic Bladder

Study ID

NCT07714694

Start date

Jul 9, 2026

Status verified date

Jul, 2026

Completion date

Oct, 2026

Anticipated

Primary completion date

Oct, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • is living in the USA
  • is male
  • is at least 22 years of age
  • can speak, read, and write in English
  • is self-catheterizing 3 or more times a day
  • has been performing unassisted, self-catheterizations, with a Hydrophilic IC, for at least 1 month
  • currently uses one of the hydrophilic ICs (length=40cm; size=Ch. 14) listed below:

1. Hollister Incorporated VaPro Pocket Nelaton Tip (clear protective tip) (SKU 70144)
2. Hollister Incorporated VaPro Pocket Coude (blue protective tip) (SKU 77144)
3. Hollister Incorporated VaPro Coude (blue protective tip) (SKU 73144)
4. Hollister Incorporated VaPro Plus Nelaton (clear protective tip) (SKU 74144)
5. Hollister Incorporated VaPro Plus Pocket Nelaton (clear protective tip) (SKU 71144)
6. Hollister Incorporated Onli Nelaton (SKU: 82144-30)
7. Hollister Incorporated Onli Coudé (SKU: 85144)
8. Wellspect LoFric Origo Nelaton (SKU: 443 14 40)
9. Wellspect LoFric Origo Tiemann/Coudé (SKU: 444 14 40)
10. Wellspect LoFric Origo Flexible Coudé with protective sleeve (SKU: 449 14 40)
11. Wellspect LoFric Origo Flexible Coudé with insertion grip (SKU: 447 14 40)
12. Coloplast SpeediCath Standard Male (SKU: 28414)
13. Coloplast SpeediCath Male Coudé Tip (SKU: 28494)
14. Coloplast SpeediCath Flex Coudé Pro (SKU: 20014)
15. Convatec GentleCath Glide Male Straight Tip (SKU: 421567)
16. Convatec GentleCath Glide Male Tiemann Tip (SKU: 421910)
17. Convatec GentleCath Air Male Straight Tip (SKU:510690)
18. Convatec GentleCath Air Male Coude Tip (SKU:510696)
19. Convatec GentleCath Hydrophilic, 14FR, Straight (SKU: 508996)
20. Convatec GentleCath Hydrophilic, 14FR, Coude (SKU: 509001)
21. Convatec Cure - Hydrophilic Cure Catheter Straight Tip (SKU: HM14)
22. Convatec Cure - Hydrophilic Cure Catheter Coudé Tip (SKU: HM14C)
23. Bard - Magic3® Go Male, 14FR, Straight (SKU:53814G)
24. Bard - Magic3® Go Male, 14FR, Coude (SKU:50814G)
25. Bard - Magic3®, 14FR, Straight (SKU: 53614G)
26. Bard - Magic3®, 14FR, Straight (SKU: 53614) aa. Bard - Magic3®, 14FR, Coude (SKU: 50614)
  • is willing and able to follow the study protocol procedures including completing online questionnaires as demonstrated by signing the Informed Consent
  • is willing to switch from their current, typical intermittent catheter to the study-provided study products (e.g., study catheters) during the latter portion of the study
  • is willing to provide permission via the study informed consent and HIPAA Authorization Form for study staff to contact prescribing healthcare provider for a copy of their active prescription. Alternatively subject can opt to provide study staff with their active prescription.

Exclusion Criteria:

  • is currently receiving chemotherapy, has received chemotherapy within the past 30 days, or is scheduled to receive chemotherapy during the study (i.e., in the next 34 days)
  • is currently undergoing, has previously underwent, or is planning to undergo radiation therapy to the bladder, prostate, or rectum during the study (i.e., in the next 34 days)
  • is currently using one or more of the following oral or injectable steroid therapies for 30 days or more:

1. Acthar Gel
2. corticotropin
3. Agamree
4. vamorolone
5. budesonide
6. Cortef
7. hydrocortisone
8. Cortrophin Gel
9. corticotrophin
10. dexamethasone
11. deflazacort
12. prednisone
13. Emflaza
14. Eohilia
15. fludrocortisone
16. Jaythari
17. Orapred ODT
18. prednisolone
19. Pyquvi
20. Rayos
21. Tarpeyo
22. Uceris
  • currently has urinary tract infection (UTI) symptoms or has been diagnosed with a UTI by a healthcare provider in the last 2 weeks
  • has a retracted penis
  • has skin irritation or lesions (sores) on the penis
  • Performs non-urethral catheterization
  • Has participated in a study involving actual use of a study urethral IC (i.e. inserting/removing) within the last 30 days
  • Is currently an employee of Hollister Incorporated or any other intermittent catheter manufacturer.

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Investigational Catheter

Participants will first use 30 of their usual intermittent catheters and then switch to 30 study catheters in a fixed-sequence, within-participant design. All participants receive the same study catheter; responses from the usual-catheter period provide within-participant control context.

Interventions

An intermittent urethral urinary catheter with a tip, tube and drainage eyelets

An intermittent urethral urinary catheter with a tip, tube and drainage eyelets

Primary outcome measure

  • Incidence of Health Changes and Adverse Events During Usual-Catheter and Investigational-Catheter Use [ Time Frame: Through completion of both catheter-use periods, approximately 6 to 20 days ]
  • Participant-Reported Overall Ease of Use of the Catheter [ Time Frame: Through completion of both catheter-use periods, approximately 6 to 20 days ]

Central Contacts and Locations

Locations

Hollister Incorporated

Recruiting

Libertyville, Illinois, United States, 60048

Contacts

Hollister Incorporated

(847) 680-1000researchstudy@hollister.com

More Information

Sponsor

Hollister Incorporated

Last update posted

Jul 20, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Hollister Incorporated on 2026-07-20.